Clinical Professor of Ophthalmology, USC School of Medicine
Ophthalmology
Dr. David N. Boyer, MD
|
|
Give Review
Dr. David N. Boyer practices Ophthalmology. He received 5 awards: "Top Doctors:LA Area", "Top Doctors:Southern California", "Top MD", "Fellow (FAAO)" and "Super Doctor". David Boyer is also a published MD. He has 69 publication published. The most recent publication is: Surfing-related ocular injuries.
Publications
- Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase...
- Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
- Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
- Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.
- PROSPECTIVE EVALUATION OF VISUAL ACUITY AGREEMENT BETWEEN STANDARD EARLY TREATMENT DIABETIC RETINOPATHY STUDY CHART AND A HANDHELD EQUIVALENT IN EYES WITH RETINAL PATH...
- Macular Atrophy Progression and 7-Year Vision Outcomes in Subjects From the ANCHOR, MARINA, and HORIZON Studies: the SEVEN-UP Study.
- Treatment of Diabetic Macular Edema with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase That Activates Tie2.
- Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: The 24-Week Results of the VIBRANT Study.
- Intravitreal Aflibercept for Diabetic Macular Edema.
- Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
- Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema.
- Intravitreal Aflibercept Injection for Macular Edema Due to Central Retinal Vein Occlusion: Two-Year Results from the COPERNICUS Study.
- Cosmetic Facial Fillers and Severe Vision Loss.
- Inherited Mitochondrial DNA Variants Can Affect Complement, Inflammation, and Apoptosis Pathways: Insights into Mitochondrial-Nuclear Interactions.
- Anti-vascular endothelial growth factor therapy for diabetic macular edema.
- Molecular and bioenergetic differences between cells with African versus European inherited mitochondrial DNA haplogroups: Implications for population susceptibility t...
- Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab: The RETAIN Study.
- CLINICAL COURSE OF VITREOMACULAR ADHESION MANAGED BY INITIAL OBSERVATION.
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials: RISE and RIDE.
- Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON: A Multicenter Cohort Study (SEVEN-UP).
- Dexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular Edema.
- Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
- Mitochondrial DNA Variants Mediate Energy Production and Expression Levels for CFH, C3 and EFEMP1 Genes: Implications for Age-Related Macular Degeneration.
- Mitochondrial DNA haplogroups confer differences in risk for age-related macular degeneration: a case control study.
- Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials.
- Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion: Six-Month Results of the Phase 3 COPERNICUS Study.
- Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
- A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
- Antisense oligonucleotide therapy in diabetic retinopathy.
- Mitochondrial DNA haplogroups associated with age-related macular degeneration.
- Chronic central serous chorioretinopathy: photodynamic therapy.
- Iatrogenic choroidal neovascularization occurring in patients undergoing macular surgery.
- Management of pupillary block glaucoma in phakic patients after vitrectomy with silicone oil injection.
- Alu DNA polymorphism in ACE gene is protective for age-related macular degeneration.
- Human Retinal Transmitochondrial Cybrids with J or H mtDNA Haplogroups Respond Differently to Ultraviolet Radiation: Implications for Retinal Diseases.
- A new choroidal mass in a patient with known metastatic leiomyosarcoma: importance of fine-needle aspirate biopsy in diagnostic certainty and treatment planning.
- Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients.
- Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
- Effect of adjunctive diclofenac with verteporfin therapy to treat choroidal neovascularization due to age-related macular degeneration: phase II study.
- Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study.
- Outcomes associated with ganciclovir implants in patients with AIDS-related cytomegalovirus retinitis.
- Ranibizumab for neovascular age-related macular degeneration.
- Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
- Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
- Efficacy of verteporfin photodynamic therapy on laser-induced choroidal neovascularization and the ancillary effect on diabetic microvasculopathy.
- Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
- Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.
- Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study.
- Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.
- The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.
- Potential complication associated with removal of ganciclovir implants.
- Characterization of retinal and blood mitochondrial DNA from age-related macular degeneration patients.
- Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome.
- Surfing-related ocular injuries.
- Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results.
- A clinical, histopathologic, and electron microscopic study of Pneumocystis carinii choroiditis.
- Autogenous fascial grafts for exposed retinal buckles.
- An objective analysis of proliferative diabetic retinopathy before and after pars plana vitrectomy.
- Intraocular carbon dioxide laser photocautery.
- Intraocular carbon dioxide laser photocautery. II. Preliminary report of clinical trials.
- Pneumatic retinopexy. Surgical results.
- Pars plana transvitreal carbon dioxide laser photocautery: a new surgical technique.
- Save your sight. Eye disease and HIV.
- Sequential retinal breaks following a spontaneous initial retinal break.
- Miniaturized intraocular carbon dioxide laser photosurgical system for multi-incision vitrectomy.
- Intraocular carbon dioxide laser photosurgery.
- Retinal artery embolization from a calcified bicuspid aortic valve causing amaurosis fugax.
- Respiratory viral infections within one year after pediatric lung transplant.
Schools
Wayne State University
Sinai Grace Hospital
Doctors Specialties
- Psychiatry
- Ophthalmology
Accepted Insurances
Awards
- Top Doctors:LA Area
- Top Doctors:Southern California
- Top MD
- Fellow (FAAO)
- Super Doctor
Education
-
Wills Eye Hospital -
University of Southern California - LAC+USC Medical Center -
Rosalind Franklin University of Medicine and Science
Hospital
-
White Memorial Medical Center -
Northridge Hospital Medical Center -
Cedars-Sinai Medical Center -
Torrance Memorial Medical Center
Drug Facts
| NPI NUMBER | 1063648681 | |
| NPPES Provider LastName | BOYER | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 296401472 | |
| NPPES Provider State | SC | |
| Specialty Description | Family Practice | |
| Total Claim Count | 396.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 40.0 | |
| Percent Opioid Claims | 10.1 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1063648681 |
| Last Name Of The Provider | BOYER |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Saba Mansoor, MD |
|
|
Dr. Dennis L. Kilpatrick, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pamela T. Frazier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William C. Offenkrantz, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard M. Kootman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alan J. Gordon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amy J. Laurent, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joanne Shen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gretchen B. Alexander, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harold J. Berger, MD
This Doctor is OpenDoctor Recommended.
|